Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R S Mannel

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Gynecologic Oncology|January 17, 2013
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group studyR J Schilder, M W Sill, H A Lankes, et al.
Gynecologic Oncology|May 1, 2022
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometriumC G Jackson, K N Moore, L Cantrell, et al.
Gynecologic Oncology|November 6, 2025
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovaryC Washington, Shailendra Kumar Dhar Dwivedi, C Gunderson-Jackson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2016
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)P H Thaker, R Salani, W E Brady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 14, 2025
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008S Y Ryu, W Deng, K Albuquerque, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners studyB J Monk, M F Brady, C Aghajanian, et al.
Gynecologic Oncology|September 9, 2022
Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safeW L Van der Kolk, A G J Van der Zee, B M Slomovitz, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Gynecologic Oncology|January 17, 2013
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group studyR J Schilder, M W Sill, H A Lankes, et al.
Gynecologic Oncology|May 1, 2022
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometriumC G Jackson, K N Moore, L Cantrell, et al.
Gynecologic Oncology|November 6, 2025
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovaryC Washington, Shailendra Kumar Dhar Dwivedi, C Gunderson-Jackson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2016
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)P H Thaker, R Salani, W E Brady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 14, 2025
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008S Y Ryu, W Deng, K Albuquerque, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners studyB J Monk, M F Brady, C Aghajanian, et al.
Gynecologic Oncology|September 9, 2022
Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safeW L Van der Kolk, A G J Van der Zee, B M Slomovitz, et al.
Pageof 4